Amgen Q1 2026 revenue rises 6% to $8.6 billion; full-year guidance lifted

Amgen reported first-quarter 2026 total revenue of $8.6 billion, up 6%, and non-GAAP EPS of $5.15 against $4.90 a year earlier. Free cash flow reached $1.5 billion. Both ends of the full-year guidance moved up slightly, with revenue now $37.1-38.5 billion and non-GAAP EPS $21.70-23.10, which is a modest raise from the February ranges.

• Q1 2026 total revenues $8.6 billion, up 6%; product sales up 4%
• Non-GAAP EPS $5.15 vs $4.90; GAAP EPS $3.34 vs $3.20
• Free cash flow $1.5 billion vs $1.0 billion a year earlier
• 2026 total revenue guidance raised to $37.1-38.5 billion from $37.0-38.4 billion
• 2026 non-GAAP EPS guidance raised to $21.70-23.10 from $21.60-23.00

SEC filing 8-K · accession 0000318154-26-000054 · sec.gov ↗